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Abstract
Randomized controlled trials (RCTs) are considered the gold standard for clinical research, thus having a high
impact on clinical guidelines and our daily patients’ care. However, various treatment strategies which we consider
“evidence based” have never been subject to a prospective RCT, as we would rate it unethical to withheld an
established treatment to individuals in an placebo controlled trial.
In a recent BMC Anesthesiology publication, Trentino et al. analyzed the usefulness of observational studies in assessing
benefit and risk of different transfusion strategies. The authors nicely reviewed and summarized similarities and
differences, advantages and limitations, between different study types frequently used in transfusion medicine.
In this interesting article, the authors conclude, that ‘when comparing the results of observational studies with
RCTs assessing transfusion outcomes, it is important that one consider not only the study method, but also the
key elements of the study design’. Thus, in this commentary we now discuss the pro’s and con’s of different
study types, even irrespective of transfusion medicine.
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Background
Over the past decades, requirements for the design of
clinical studies increased, favouring randomized, con-
trolled trials (RCTs). In this context, benefit and risk as-
sociated with allogeneic blood product transfusions have
been discussed and debated in a large number of publi-
cations. If only a few prospective RCTs compared a lib-
eral with a restrictive transfusion strategy in different
medical and surgical populations, a large number of
retrospective observational studies have been published
leading to sometimes conflicting results [1, 2]. In a re-
cent BMC Anesthesiology publication, Trentino et al.
addressed an important question: “Should we ignore the
results obtained from observational studies when asses-
sing the benefit and the risk of different transfusion
strategies [3]?”. The authors nicely reviewed and sum-
marized the similarities and differences, advantages and
limitations, between different study designs frequently
used in transfusion medicine. The authors concluded
that “when comparing the results of observational stud-
ies with RCTs assessing transfusion outcomes, it is
important that one consider not only the study method,
but also the key elements of the study design”.
Main text
With the increasing importance of evidence based medi-
cine, RCTs are now typically regarded as the “gold stand-
ard” to evaluate the efficacy of a therapy or an
intervention intended to improve outcome. Some con-
sider RCTs to be the only valid design to evaluate thera-
peutic efficacy. The strengths of RCTs are obvious and
include the development of a prospective study protocol
with strict inclusion and exclusion criteria, a well-defined
intervention, and predefined endpoints [4]. All of those be-
ing usually absent or defined ‘a posteriori’ in observational
studies, which makes the interpretation of the results diffi-
cult. However, our daily clinical practice is mainly based on
the understanding of the pathophysiology, and how any
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given interventions may influence that pathophysiology to
improve outcomes [5]. In addition, clinical decision mak-
ing is still based on behaviours and treatments which have
never been evaluated in clinical trials, considering that
some interventions may never be subject to a
randomization. As an example, it is obvious that a RCT to
assess the influence of intraoperative opioids on sympa-
thetic nervous system activation and surgical pain com-
pared to a placebo would be considered highly unethical,
and will never be performed. Thus, observational trials are
sometimes the only option to get data on specific scientific
questions.
Transfusion medicine is a good example of how patho-
physiology can influence the effectiveness or safety of a
treatment when applied in different clinical circum-
stances or populations. Among various studies that com-
pared the effect of two transfusion triggers on outcomes
in different populations, some of them indicated that a
restrictive transfusion strategy (transfusion threshold
Hb > 7–8 g/dL) was at least as good as a liberal transfu-
sion strategy (transfusion threshold Hb > 9–10 g/dL)
[6, 7], while other studies suggested that a restrictive
transfusion strategy could be harmful when applied to
other populations, like patients with neoplasm or cor-
onary artery disease [8, 9]. That being said, the conflict
in results between prospective studies doesn’t mean
that we should reconsider the findings of those well-
designed trials, but this should be considered as a good
opportunity to highlight the limitations of large RCTs
and the aspect that could not be assessed by a single
study. The application of strict inclusion and exclusion
criteria often lead to the inclusion of a very small pro-
portion of the patients that we are used to deal with in
our daily practice, which means that the studied popu-
lation does not reflect the real world’. Furthermore,
when analyzing RCT one needs to take into account
the control group used. A recent meta-analysis showed
that a randomized placebo-controlled design was more
often used in studies funded by pharmaceutical com-
panies, i.e. as shown for psoriasis [10]. To test the over-
all efficiency of a new drug placebo controls are
appropriate, however comparing two different thera-
peutic options might be necessary to show that a new,
usually more expansive, treatment is superior to the
established gold standard. This is of particular import-
ance, as new medications should show their additional
benefit in comparison to existing therapeutic strategies
and not compared to placebo, which at least in some
countries, is the premise for being covered by health
care insurances [11].
Although, RCTs are Masterpieces to assess the efficacy
of a treatment in a specific population (e.g. can the treat-
ment work under ideal circumstances?), alternatives are
required to assess the effectiveness of the same therapy
(e.g. will the treatment work in real-world circum-
stances) [12]. The progresses made in term of sophisti-
cated statistical methods (e.g. multivariable logistic
regression, propensity matched analysis) have pushed
researchers to consider observational studies as an easily
accessible and cheap method to look at the safety and
effectiveness of different therapeutic strategies, without
the need to spend a lot of money randomizing a large
number of patients [13]. One might argue that large
observational trials using propensity score matching and
appropriate multivariate regression analyses might better
reflect the ‘real clinical world’ than a RCT performed in
a homogenous subgroup of patients. Most important,
the quality of the results obtained from those studies is
highly influenced by the quality of the data collected, the
quality of the method applied to adjust for potential con-
founders as well as the selection of the confounders, and
finally the quality of the interpretation of the results and
limitations.
Although it would be desirable to rely solely on RCTs
to guide clinical practice, it is simply impossible. As
illustrated in Fig. 1, the relationship between transfusion
and outcome is far more than a simple relationship be-
tween transfusion (yes/no) and outcome (yes/no). Not
only the volume of blood products transfused influences
the odds of a bad outcome [14], but the underlying con-
dition leading to the transfusion (e.g. anemia and/or
hemorrhage) is also a key player [15]. In addition,
patient’s characteristics may or may not influence the
tolerance to any of those conditions, and all of those as-
pects are crucial in the understanding of the relationship
between transfusion and outcome. If treatment of
anemia through the transfusion of small volume of RBCs
(Zone 1) may be beneficial in some circumstances (e.g.
when alternatives, like preoperative optimization with
iron, are not available), or the transfusion could be life-
saving in the context of life-threatening hemorrhage
(Zone 3) [16], there is a grey zone in-between (Zone 2)
where some patients will benefit from a transfusion
while other will be harmed by equal amounts and types
of transfusion. It is also obvious that no RCTs or obser-
vational studies will ever be able to dissociate the effect
of massive bleeding and massive transfusion (Zone 3) on
the odds of a bad outcome, since it is absolutely impos-
sible to compare massively bleeding patients that got
transfused with those who did not receive any transfu-
sions. Considering that the spectrum of transfusion
medicine is extremely large and complicated, and repre-
sents a large population of patients with different co-
morbidities and characteristics, it is extremely challen-
ging to address all the different clinical scenarios into a
single RCT or observational study.
Apart from RCTs or observational studies even basic
research is currently in the focus as data obtained i.e. in
Faraoni and Schaefer BMC Anesthesiology  (2016) 16:102 Page 2 of 4
mice obviously cannot be translated one to one to
humans and the clinical setting [17]. However, it is hard
to believe that modern research would work without
animal studies, as analyzing signaling pathways in vari-
ous conditions or the investigation of new therapeutic
approaches as well as the performance of life threatening
study protocols can only be done using animals. How-
ever, especially basic research can highly benefit from as-
suring data obtained from animals by adding data from
an observational trial in humans, i.e. to validate alter-
ation, found following a defined intervention in mice, in
our clinical patients [18]. Thus, translational research
using observational studies allows us to find associations
between basic research and clinical patients’, and this
even long before new, experimental therapeutic strat-
egies could be approved and tested in RCTs.
Conclusions
Although it is important to understand the strengths
and limitations of both RCTs (efficacy studies) and ob-
servational studies (effectiveness studies), none of the
study designs should be considered in isolation since all
types of evidence rely primarily on the rigour with which
individual studies were conducted (regardless of the
methodological approach) and the care with which they
are interpreted [19]. Interpretation of the results ob-
tained from both RCTs and observational studies can
help understand the efficacy/effectiveness and safety of a
therapeutic option. Meta-analyses using both RCT and
observational studies should be used to highlight some
questions that neither a RCT, nor an observational study
would have the ability to solve by themselves. As sug-
gested by Trentino et al. [3], the results obtained from
both RCTs and observational studies should be inter-
preted knowing the characteristics of the population,
including the control group used and the method used
to assess the efficacy and the safety of the treatment,
with a good understanding of the potential limitations
and aspects that the study was not able to address.
While dressing the general picture, both RCTs and ob-
servational studies should be included in our reflection,
considering that each study design could bring an im-
portant piece of information in the interpretation of the
safety, efficacy, and effectiveness of a therapeutic option
in different populations. Regardless of the study type, it
remains our accountability to scrutinize methods, con-
trols and conclusions drawn in all the paper we read.
Thus reviewing and discussing this, as done by Trentino
et al. in their recent paper regarding transfusion medi-
cine, is highly helpful.
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Fig. 1 Relationship between the volume of red blood cells transfused and the odds of a bad outcome in two different patients, after taking into
consideration the underlying condition (e.g. anemia [Zone 1], hemorrhage [Zone 3]) and the volume of blood loss
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